{"id":"fidaxomicin","rwe":[{"pmid":"41846263","year":"2026","title":"Ionomycin Exhibits Potent and Selective Bactericidal Activity Against Clostridioides difficile Through Calcium-Dependent Membrane Disruption.","finding":"","journal":"MicrobiologyOpen","studyType":"Clinical Study"},{"pmid":"41841080","year":"2026","title":"An Unlikely Culprit: Novel Case of Vancomycin Oral Solution-Induced Agranulocytosis.","finding":"","journal":"Cureus","studyType":"Clinical Study"},{"pmid":"41813198","year":"2026","title":"Diagnosis and Treatment of Clostridioides difficile Infection.","finding":"","journal":"Journal of Nippon Medical School = Nippon Ika Daigaku zasshi","studyType":"Clinical Study"},{"pmid":"41808698","year":"2026","title":"Refractory Clostridioides difficile Colitis in a Patient With Hidradenitis Suppurativa: Consequences of Long-Term Clindamycin and Multi-agent Anti-TNF Therapy.","finding":"","journal":"Cureus","studyType":"Clinical Study"},{"pmid":"41770247","year":"2026","title":"Ribotype distribution of Clostridioides difficile isolated from patients with diarrhea in Ahvaz, Iran.","finding":"","journal":"Acta microbiologica et immunologica Hungarica","studyType":"Clinical Study"}],"_fda":{"id":"a9a2681d-631b-f559-de45-a06b3723e65c","set_id":"6cc3e803-8935-f9b3-ab7f-fef8b1c02070","openfda":{"nui":["M0028311","N0000175431"],"upc":["0360505483327"],"unii":["Z5N076G8YQ"],"route":["ORAL"],"rxcui":["1111106"],"spl_id":["a9a2681d-631b-f559-de45-a06b3723e65c"],"brand_name":["Fidaxomicin"],"spl_set_id":["6cc3e803-8935-f9b3-ab7f-fef8b1c02070"],"package_ndc":["60505-4833-2"],"product_ndc":["60505-4833"],"generic_name":["FIDAXOMICIN"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Macrolides [CS]"],"substance_name":["FIDAXOMICIN"],"pharm_class_epc":["Macrolide Antibacterial [EPC]"],"manufacturer_name":["Apotex Corp."],"application_number":["ANDA219559"],"is_original_packager":[true]},"version":"2","pregnancy":["8.1 Pregnancy Risk Summary The limited available data on use of fidaxomicin tablets in pregnant women are insufficient to inform any drug-associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes. Embryo-fetal reproduction studies in rats and rabbits dosed intravenously during organogenesis revealed no evidence of harm to the fetus at fidaxomicin and OP-1118 (its main metabolite) exposures 65-fold or higher than the clinical exposure at the fidaxomicin tablets recommended dose [see Data]. The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data In pregnant rats, fidaxomicin was administered intravenously at doses of 4, 8, and 15 mg/kg/day from gestation day 6 through 17 (during the period of organogenesis). No embryo/fetal effects were noted in this study at exposures (AUC) 193-fold higher for fidaxomicin, and 65-fold higher for OP-1118 than the clinical exposure at the fidaxomicin tablets recommended dose. In pregnant rabbits, fidaxomicin was administered intravenously at doses of 2, 4, and 7.5 mg/kg/day from gestation day 6 through 18 (during the period of organogenesis). No embryo/fetal effects were noted in this study at exposures 66-fold higher for fidaxomicin, and 245-fold higher for OP-1118 than the clinical exposure at the fidaxomicin tablets recommended dose."],"overdosage":["10 OVERDOSAGE No cases of acute overdose have been reported in humans. No drug-related adverse effects were seen in dogs dosed with fidaxomicin tablets at 9,600 mg/day (over 100 times the human dose, scaled by weight) for 3 months."],"description":["11 DESCRIPTION Fidaxomicin tablets (fidaxomicin) is a macrolide antibacterial drug for oral administration. Its CAS chemical name is Oxacyclooctadeca-3,5,9,13,15-pentaen-2-one, 3-[[[6-deoxy-4- O -(3,5-dichloro-2-ethyl-4,6-dihydroxybenzoyl)-2- O -methyl-β-D-mannopyranosyl]oxy]methyl]-12-[[6-deoxy-5- C -methyl-4- O -(2-methyl-1-oxopropyl)-β-D- lyxo -hexopyranosyl]oxy]-11-ethyl-8-hydroxy-18-[(1 R )-1-hydroxyethyl]-9,13,15-trimethyl-,(3 E ,5 E ,8 S ,9 E ,11 S ,12 R ,13 E ,15 E ,18 S )-.The structural formula of fidaxomicin is shown in Figure 1. Figure 1: Structural Formula of Fidaxomicin Fidaxomicin tablets are film-coated and contain 200 mg of fidaxomicin per tablet and the following inactive ingredients: butylated hydroxytoluene, hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, pregelatinized starch, sodium starch glycolate, talc, and titanium dioxide."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Fidaxomicin tablets are white to off-white, capsule shape, biconvex film-coated tablet. Engraved “F200” on one side, “APO” on the other side. Fidaxomicin tablets are supplied as bottles of 20 tablets (NDC 60505-4833-2). 16.2 Storage Store fidaxomicin tablets at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). See USP Controlled Room Temperature. Store in the original bottle."],"microbiology":["12.4 Microbiology Mechanism of Action Fidaxomicin is a fermentation product obtained from the Actinomycete Dactylosporangium aurantiacum. Fidaxomicin is a macrolide antibacterial drug that inhibits RNA synthesis by binding to RNA polymerases. Fidaxomicin is bactericidal against C. difficile in vitro , and demonstrates a post-antibiotic effect vs. C. difficile of 6 to 10 hrs. Resistance Fidaxomicin demonstrates no in vitro cross-resistance with other classes of antibacterial drugs. In vitro studies indicate a low frequency of spontaneous resistance to fidaxomicin in C. difficile (ranging from <1.4 × 10 -9 to 12.8 × 10 -9 ). A specific mutation (Val-ll43-Gly) in the beta subunit of RNA polymerase is associated with reduced susceptibility to fidaxomicin. This mutation was created in the laboratory and seen during clinical trials in a C. difficile isolate obtained from an adult subject treated with fidaxomicin tablets who had recurrence of CDAD. The fidaxomicin minimum inhibitory concentration (MIC) of the C. difficil e isolate from this subject increased from a baseline of 0.06 mcg/mL to 16 mcg/mL at the time of CDAD recurrence. Interaction With Other Antimicrobials Fidaxomicin and its main metabolite OP-1118 do not exhibit any antagonistic interaction with other classes of antibacterial drugs. Synergistic interactions of fidaxomicin and OP-1118 have been observed in vitro with rifampin and rifaximin against C. difficile . Antimicrobial Activity Fidaxomicin has been shown to be active against most isolates of Clostridioides ( formerly Clostridium) difficile , both in vitro and in clinical infections [see Indications and Usage ( 1 )]. Susceptibility Testing For specific information regarding susceptibility test interpretive criteria, and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC."],"geriatric_use":["8.5 Geriatric Use Of the total number of patients in controlled trials of fidaxomicin tablets, 50% were 65 years of age and over, while 31% were 75 and over. No overall differences in safety or effectiveness of fidaxomicin tablets compared to vancomycin were observed between these subjects and younger subjects. In controlled trials, elderly patients (≥65 years of age) had higher plasma concentrations of fidaxomicin and its main metabolite, OP-1118, versus non-elderly patients (<65 years of age) [see Clinical Pharmacology ( 12.3 )]. However, greater exposures in elderly patients were not considered to be clinically significant. No dose adjustment is recommended for elderly patients."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of fidaxomicin tablets have not been established in pediatric patients younger than 6 months of age. Pediatric use information is approved for Cubist Pharmaceuticals LLC's DIFICID ® (fidaxomicin) tablets. However, due to Cubist Pharmaceuticals LLC's marketing exclusivity rights, this drug product is not labeled with that information."],"effective_time":"20260213","clinical_studies":["14 CLINICAL STUDIES 14.1 Clinical Studies of Fidaxomicin Tablets in Adult Patients with CDAD In two randomized, double-blinded trials, a non-inferiority design was utilized to demonstrate the efficacy of fidaxomicin tablets (200 mg tablets twice daily for 10 days) compared to vancomycin (125 mg four times daily for 10 days) in adults with CDAD. Enrolled patients were 18 years of age or older and received no more than 24 hours of pretreatment with vancomycin or metronidazole. CDAD was defined by >3 unformed bowel movements (or >200 mL of unformed stool for subjects having rectal collection devices) in the 24 hours before randomization, and presence of either C. difficile toxin A or B in the stool within 48 hours of randomization. Enrolled patients had either no prior CDAD history or only one prior CDAD episode in the past three months. Subjects with life-threatening/fulminant infection, hypotension, septic shock, peritoneal signs, significant dehydration, or toxic megacolon were excluded. The demographic profile and baseline CDAD characteristics of enrolled subjects were similar in the two trials. Patients had a median age of 64 years, were mainly white (90%), female (58%), and inpatients (63%). The median number of bowel movements per day was 6, and 37% of subjects had severe CDAD (defined as 10 or more unformed bowel movements per day or WBC ≥15,000/mm 3 ). Diarrhea alone was reported in 45% of patients and 84% of subjects had no prior CDAD episode. The primary efficacy endpoint was the clinical response rate at the end of treatment, based upon improvement in diarrhea or other symptoms such that, in the investigator's judgment, further CDAD treatment was not needed. An additional efficacy endpoint was sustained clinical response 25 days after the end of treatment. Sustained response was evaluated only for patients who were clinical successes at the end of treatment. Sustained response was defined as clinical response at the end of treatment, and survival without proven or suspected CDAD recurrence through 25 days beyond the end of treatment. The results for clinical response at the end of treatment in both trials, shown in Table 6, indicate that fidaxomicin tablets is non-inferior to vancomycin based on the 95% confidence interval (CI) lower limit being greater than the non-inferiority margin of -10%. The results for sustained clinical response at the end of the follow-up period, also shown in Table 6, indicate that fidaxomicin tablets is superior to vancomycin on this endpoint. Since clinical success at the end of treatment and mortality rates were similar across treatment arms (approximately 6% in each group), differences in sustained clinical response were due to lower rates of proven or suspected CDAD during the follow-up period in fidaxomicin tablets patients. Table 6: Clinical Response Rates at End-of-Treatment and Sustained Response at 25 days Post-Treatment in Adult Patients Clinical Response at End of Treatment Sustained Response at 25 days Post- Treatment Fidaxomicin % (N) Vancomycin % (N) Difference (95% CI)* Fidaxomicin % (N) Vancomycin % (N) Difference (95% CI)* Trial 1 88% (N=289) 86% (N=307) 2.6% (-2.9%, 8.0%) 70% (N=289) 57% (N=307) 12.7% (4.4%, 20.9%) Trial 2 88% (N=253) 87% (N=256) 1.0% (-4.8%, 6.8%) 72% (N=253) 57% (N=256) 14.6% (5.8%, 23.3%) * Confidence interval (CI) was derived using Wilson's score method. Approximately 5%-9% of the data in each trial and treatment arm were missing sustained response information and were imputed using multiple imputation method. Restriction Endonuclease Analysis (REA) was used to identify C. difficile baseline isolates in the BI group, isolates associated with increasing rates and severity of CDAD in the US in the years prior to the clinical trials. Similar rates of clinical response at the end of treatment and proven or suspected CDAD during the follow-up period were seen in fidaxomicin-treated and vancomycin-treated patients infected with a BI isolate. However, fidaxomicin tablets did not demonstrate superiority in sustained clinical response when compared with vancomycin (Table 7). Table 7: Sustained Clinical Response at 25 Days after Treatment by C. difficile REA Group at Baseline in Adult Patients Trial 1 Initial C. difficile Group Fidaxomicin n/N (%) Vancomycin n/N (%) Difference (95% CI)* BI Isolates 44/76 (58%) 52/82 (63%) -5.5% (-20.3%, 9.5%) Non-BI Isolates 105/126 (83%) 87/131 (66%) 16.9% (6.3%, 27.0%) Trial 2 Initial C. difficile Group Fidaxomicin n/N (%) Vancomycin n/N (%) Difference (95% CI)* BI Isolates 42/65 (65%) 31/60 (52%) 12.9% (-4.2%, 29.2%) Non-BI Isolates 109/131 (83%) 77/121 (64%) 19.6% (8.7%, 30.0%) * Interaction test between the effect on sustained response rate and BI versus non-BI isolates using logistic regression (p-values: trial 1: 0.009; trial 2: 0.29). Approximately 25% of the mITT population were missing data for REA group. Confidence intervals (CI) were derived using Wilson's score method. Pediatric use information is approved for Cubist Pharmaceuticals LLC's DIFICID ® (fidaxomicin) tablets. However, due to Cubist Pharmaceuticals LLC's marketing exclusivity rights, this drug product is not labeled with that information."],"pharmacodynamics":["12.2 Pharmacodynamics Fidaxomicin acts locally in the gastrointestinal tract on C. difficile. In a dose-ranging trial (N=48) of fidaxomicin using 50 mg, 100 mg, and 200 mg twice daily for 10 days, a dose-response relationship was observed for efficacy."],"pharmacokinetics":["12.3 Pharmacokinetics The pharmacokinetic parameters of fidaxomicin and its main metabolite OP-1118 following a single dose of 200 mg in healthy adult males (N=14) are summarized in Table 4. Table 4: Mean (± Standard Deviation) Pharmacokinetic Parameters of Fidaxomicin 200 mg in Healthy Adult Males Parameter Fidaxomicin OP- 1118 N Value N Value C max (ng/mL) 14 5.20 ± 2.81 14 12.0 ± 6.06 T max (h)* 14 2.00 (1.00-5.00) 14 1.02 (1.00-5.00) AUC 0-t (ng-h/mL) 14 48.3 ± 18.4 14 103 ± 39.4 AUC 0-∞ (ng-h/mL) 9 62.9 ± 19.5 10 118 ± 43.3 t 1/2 (h) 9 11.7 ± 4.80 10 11.2 ± 3.01 * T max , reported as median (range). C max , maximum observed concentration; T max , time to maximum observed concentration; AUC 0-t , area under the concentration-time curve from time 0 to the last measured concentration; AUC 0-∞, area under the concentration-time curve from time 0 to infinity; t 1/2 , elimination half-life Absorption Fidaxomicin has minimal systemic absorption following oral administration, with plasma concentrations of fidaxomicin and OP-1118 in the ng/mL range at the therapeutic dose. In fidaxomicin-treated patients from controlled trials, plasma concentrations of fidaxomicin and OP-1118 obtained within the T max window (1 to 5 hours) were approximately 2- to 6-fold higher than C max values in healthy adults. Following administration of fidaxomicin tablets 200 mg twice daily for 10 days, OP-1118 plasma concentrations within the T max window were approximately 50%-80% higher than on Day 1, while concentrations of fidaxomicin were similar on Days 1 and 10. In a food-effect study involving administration of fidaxomicin tablets to healthy adults (N=28) with a high-fat meal versus under fasting conditions, C max of fidaxomicin and OP-1118 decreased by 21.5% and 33.4%, respectively, while AUC 0-t remained unchanged. This decrease in C max is not considered clinically significant, and thus, fidaxomicin tablets may be administered with or without food. Distribution Fidaxomicin is mainly confined to the gastrointestinal tract following oral administration. In selected patients (N=8) treated with fidaxomicin tablets 200 mg twice daily for 10 days from controlled trials, fecal concentrations of fidaxomicin and OP-1118 obtained within 24 hours of the last dose ranged from 639 to 2,710 mcg /g and 213 to 1,210 mcg/g, respectively. In contrast, plasma concentrations of fidaxomicin and OP-1118 within the T max window (1 to 5 hours) ranged 2 to 179 ng/mL and 10 to 829 ng/mL, respectively. Elimination Metabolism Fidaxomicin is primarily transformed by hydrolysis at the isobutyryl ester to form its main and microbiologically active metabolite, OP-1118. Metabolism of fidaxomicin and formation of OP-1118 are not dependent on cytochrome P450 (CYP) enzymes. At the therapeutic dose, OP-1118 was the predominant circulating compound in healthy adults, followed by fidaxomicin. Excretion Fidaxomicin is mainly excreted in feces. In one trial of healthy adults (N=11), more than 92% of the dose was recovered in the stool as fidaxomicin and OP-1118 following single doses of 200 mg and 300 mg. In another trial of healthy adults (N=6), 0.59% of the dose was recovered in urine as OP-1118 only following a single dose of 200 mg. Specific Populations Geriatric Patients In controlled trials of patients treated with fidaxomicin tablets 200 mg twice daily for 10 days, mean and median values of fidaxomicin and OP-1118 plasma concentrations within the T max window (1 to 5 hours) were approximately 2- to 4-fold higher in elderly patients (≥65 years of age) versus non-elderly patients (<65 years of age). Despite greater exposures in elderly patients, fidaxomicin and OP-1118 plasma concentrations remained in the ng/mL range [see Use in Specific Populations (8.5)]. Pediatric Patients Pediatric use information is approved for Cubist Pharmaceuticals LLC's DIFICID ® (fidaxomicin) tablets. However, due to Cubist Pharmaceuticals LLC's marketing exclusivity rights, this drug product is not labeled with that information. Male and Female Patients Plasma concentrations of fidaxomicin and OP-1118 within the T max window (1 to 5 hours) did not vary by gender in patients treated with fidaxomicin tablets 200 mg twice daily for 10 days from controlled trials. No dose adjustment is recommended based on gender. Patients with Renal Impairment In controlled trials of patients treated with fidaxomicin tablets 200 mg twice daily for 10 days, plasma concentrations of fidaxomicin and OP-1118 within the T max window (1 to 5 hours) did not vary by severity of renal impairment (based on creatinine clearance) between mild (51 to 79 mL/min), moderate (31 to 50 mL/min), and severe (≤ 30 mL/min) categories. No dose adjustment is recommended based on renal function. Patients with Hepatic Impairment The impact of hepatic impairment on the pharmacokinetics of fidaxomicin has not been evaluated. Because fidaxomicin and OP-1118 do not appear to undergo significant hepatic metabolism, elimination of fidaxomicin and OP-1118 is not expected to be significantly affected by hepatic impairment. Drug Interaction Studies In vivo studies were conducted to evaluate intestinal drug-drug interactions of fidaxomicin as a P-gp substrate, P-gp inhibitor, and inhibitor of major CYP enzymes expressed in the gastrointestinal tract (CYP3A4, CYP2C9, and CYP2C19). Table 5 summarizes the impact of a co-administered drug (P-gp inhibitor) on the pharmacokinetics of fidaxomicin [see Drug Interactions ( 7.1 )]. Table 5: Pharmacokinetic Parameters of Fidaxomicin and OP-1118 in the Presence of a Co-Administered Drug Parameter Cyclosporine 200 mg + Fidaxomicin 200 mg* (N=14) Fidaxomicin 200 mg Alone (N=14) Mean Ratio of Parameters With/Without Co- Administered Drug (90% CI † ) No Effect = 1.00 N Mean N Mean Fidaxomicin C max (ng/mL) 14 19.4 14 4.67 4.15 (3.23-5.32) AUC 0-∞ (ng-h/mL) 8 114 9 59.5 1.92 (1.39-2.64) OP-1118 C max (ng/mL) 14 100 14 10.6 9.51 (6.93-13.05) AUC 0-∞ (ng-h/mL) 12 438 10 106 4.11 (3.06-5.53) * Cyclosporine was administered 1 hour before fidaxomicin. † CI - confidence interval Fidaxomicin had no significant impact on the pharmacokinetics of the following co-administered drugs: digoxin (P-gp substrate), midazolam (CYP3A4 substrate), warfarin (CYP2C9 substrate), and omeprazole (CYP2C19 substrate). No dose adjustment is warranted when fidaxomicin is co-administered with substrates of P-gp or CYP enzymes."],"adverse_reactions":["6 ADVERSE REACTIONS The most common adverse reactions in adults (incidence ≥2%) are nausea, vomiting, abdominal pain, gastrointestinal hemorrhage, anemia, and neutropenia. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp., at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adults The safety of fidaxomicin 200 mg tablets taken twice a day for 10 days was evaluated in 564 adult patients with CDAD in two active-controlled trials with 86.7% of patients receiving a full course of treatment. Thirty-three adult patients receiving fidaxomicin tablets (5.9%) withdrew from trials as a result of adverse reactions (AR). The types of AR resulting in withdrawal from the study varied considerably. Vomiting was the primary adverse reaction leading to discontinuation of dosing; this occurred at an incidence of 0.5% in both the fidaxomicin tablets and vancomycin patients in Phase 3 trials. The most common selected adverse reactions occurring in ≥2% of adult patients treated with fidaxomicin tablets are listed in Table 2. Table 2: Selected Adverse Reactions with an Incidence of ≥2% Reported in Fidaxomicin-Treated Adult Patients in Controlled Trials System Organ Class Adverse Reaction Fidaxomicin (N=564) Vancomycin (N=583) n (%) n (%) Blood and Lymphatic System Disorders Anemia 14 (2%) 12 (2%) Neutropenia 14 (2%) 6 (1%) Gastrointestinal Disorders Nausea 62 (11%) 66 (11%) Vomiting 41 (7%) 37 (6%) Abdominal Pain 33 (6%) 23 (4%) Gastrointestinal Hemorrhage 20 (4%) 12 (2%) The following adverse reactions were reported in <2% of adult patients taking fidaxomicin tablets in controlled trials: Gastrointestinal Disorders: abdominal distension, abdominal tenderness, dyspepsia, dysphagia, flatulence, intestinal obstruction, megacolon Investigations: increased blood alkaline phosphatase, decreased blood bicarbonate, increased hepatic enzymes, decreased platelet count Metabolism and Nutrition Disorders: hyperglycemia, metabolic acidosis Skin and Subcutaneous Tissue Disorders: drug eruption, pruritus, rash 6.2 Post Marketing Experience The following adverse reactions have been identified during post-approval use of fidaxomicin tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Hypersensitivity reactions (dyspnea, angioedema, rash, pruritus) Pediatric use information is approved for Cubist Pharmaceuticals LLC's DIFICID ® (fidaxomicin) tablets. However, due to Cubist Pharmaceuticals LLC's marketing exclusivity rights, this drug product is not labeled with that information."],"contraindications":["4 CONTRAINDICATIONS Fidaxomicin tablets are contraindicated in patients who have known hypersensitivity to fidaxomicin or any other ingredient in fidaxomicin tablets [see Warnings and Precautions ( 5.1 )]. Fidaxomicin tablets are contraindicated in patients who have known hypersensitivity to fidaxomicin or any other ingredient in fidaxomicin tablets. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS Fidaxomicin and its main metabolite, OP-1118, are substrates of the efflux transporter, P-glycoprotein (P-gp), which is expressed in the gastrointestinal tract. 7.1 Cyclosporine Cyclosporine is an inhibitor of multiple transporters, including P-gp. When cyclosporine was co-administered with fidaxomicin tablets, plasma concentrations of fidaxomicin and OP-1118 were significantly increased but remained in the ng/mL range [see Clinical Pharmacology ( 12.3 )]. Concentrations of fidaxomicin and OP-1118 may also be decreased at the site of action (i.e., gastrointestinal tract) via P-gp inhibition; however, concomitant P-gp inhibitor use had no attributable effect on safety or treatment outcome of fidaxomicin-treated adult patients in controlled clinical trials. Based on these results, fidaxomicin may be co-administered with P-gp inhibitors and no dose adjustment is recommended."],"mechanism_of_action":["12.1 Mechanism of Action Fidaxomicin is an antibacterial drug [see Microbiology ( 12.4 )]."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Fidaxomicin is an antibacterial drug [see Microbiology ( 12.4 )]. 12.2 Pharmacodynamics Fidaxomicin acts locally in the gastrointestinal tract on C. difficile. In a dose-ranging trial (N=48) of fidaxomicin using 50 mg, 100 mg, and 200 mg twice daily for 10 days, a dose-response relationship was observed for efficacy. 12.3 Pharmacokinetics The pharmacokinetic parameters of fidaxomicin and its main metabolite OP-1118 following a single dose of 200 mg in healthy adult males (N=14) are summarized in Table 4. Table 4: Mean (± Standard Deviation) Pharmacokinetic Parameters of Fidaxomicin 200 mg in Healthy Adult Males Parameter Fidaxomicin OP- 1118 N Value N Value C max (ng/mL) 14 5.20 ± 2.81 14 12.0 ± 6.06 T max (h)* 14 2.00 (1.00-5.00) 14 1.02 (1.00-5.00) AUC 0-t (ng-h/mL) 14 48.3 ± 18.4 14 103 ± 39.4 AUC 0-∞ (ng-h/mL) 9 62.9 ± 19.5 10 118 ± 43.3 t 1/2 (h) 9 11.7 ± 4.80 10 11.2 ± 3.01 * T max , reported as median (range). C max , maximum observed concentration; T max , time to maximum observed concentration; AUC 0-t , area under the concentration-time curve from time 0 to the last measured concentration; AUC 0-∞, area under the concentration-time curve from time 0 to infinity; t 1/2 , elimination half-life Absorption Fidaxomicin has minimal systemic absorption following oral administration, with plasma concentrations of fidaxomicin and OP-1118 in the ng/mL range at the therapeutic dose. In fidaxomicin-treated patients from controlled trials, plasma concentrations of fidaxomicin and OP-1118 obtained within the T max window (1 to 5 hours) were approximately 2- to 6-fold higher than C max values in healthy adults. Following administration of fidaxomicin tablets 200 mg twice daily for 10 days, OP-1118 plasma concentrations within the T max window were approximately 50%-80% higher than on Day 1, while concentrations of fidaxomicin were similar on Days 1 and 10. In a food-effect study involving administration of fidaxomicin tablets to healthy adults (N=28) with a high-fat meal versus under fasting conditions, C max of fidaxomicin and OP-1118 decreased by 21.5% and 33.4%, respectively, while AUC 0-t remained unchanged. This decrease in C max is not considered clinically significant, and thus, fidaxomicin tablets may be administered with or without food. Distribution Fidaxomicin is mainly confined to the gastrointestinal tract following oral administration. In selected patients (N=8) treated with fidaxomicin tablets 200 mg twice daily for 10 days from controlled trials, fecal concentrations of fidaxomicin and OP-1118 obtained within 24 hours of the last dose ranged from 639 to 2,710 mcg /g and 213 to 1,210 mcg/g, respectively. In contrast, plasma concentrations of fidaxomicin and OP-1118 within the T max window (1 to 5 hours) ranged 2 to 179 ng/mL and 10 to 829 ng/mL, respectively. Elimination Metabolism Fidaxomicin is primarily transformed by hydrolysis at the isobutyryl ester to form its main and microbiologically active metabolite, OP-1118. Metabolism of fidaxomicin and formation of OP-1118 are not dependent on cytochrome P450 (CYP) enzymes. At the therapeutic dose, OP-1118 was the predominant circulating compound in healthy adults, followed by fidaxomicin. Excretion Fidaxomicin is mainly excreted in feces. In one trial of healthy adults (N=11), more than 92% of the dose was recovered in the stool as fidaxomicin and OP-1118 following single doses of 200 mg and 300 mg. In another trial of healthy adults (N=6), 0.59% of the dose was recovered in urine as OP-1118 only following a single dose of 200 mg. Specific Populations Geriatric Patients In controlled trials of patients treated with fidaxomicin tablets 200 mg twice daily for 10 days, mean and median values of fidaxomicin and OP-1118 plasma concentrations within the T max window (1 to 5 hours) were approximately 2- to 4-fold higher in elderly patients (≥65 years of age) versus non-elderly patients (<65 years of age). Despite greater exposures in elderly patients, fidaxomicin and OP-1118 plasma concentrations remained in the ng/mL range [see Use in Specific Populations (8.5)]. Pediatric Patients Pediatric use information is approved for Cubist Pharmaceuticals LLC's DIFICID ® (fidaxomicin) tablets. However, due to Cubist Pharmaceuticals LLC's marketing exclusivity rights, this drug product is not labeled with that information. Male and Female Patients Plasma concentrations of fidaxomicin and OP-1118 within the T max window (1 to 5 hours) did not vary by gender in patients treated with fidaxomicin tablets 200 mg twice daily for 10 days from controlled trials. No dose adjustment is recommended based on gender. Patients with Renal Impairment In controlled trials of patients treated with fidaxomicin tablets 200 mg twice daily for 10 days, plasma concentrations of fidaxomicin and OP-1118 within the T max window (1 to 5 hours) did not vary by severity of renal impairment (based on creatinine clearance) between mild (51 to 79 mL/min), moderate (31 to 50 mL/min), and severe (≤ 30 mL/min) categories. No dose adjustment is recommended based on renal function. Patients with Hepatic Impairment The impact of hepatic impairment on the pharmacokinetics of fidaxomicin has not been evaluated. Because fidaxomicin and OP-1118 do not appear to undergo significant hepatic metabolism, elimination of fidaxomicin and OP-1118 is not expected to be significantly affected by hepatic impairment. Drug Interaction Studies In vivo studies were conducted to evaluate intestinal drug-drug interactions of fidaxomicin as a P-gp substrate, P-gp inhibitor, and inhibitor of major CYP enzymes expressed in the gastrointestinal tract (CYP3A4, CYP2C9, and CYP2C19). Table 5 summarizes the impact of a co-administered drug (P-gp inhibitor) on the pharmacokinetics of fidaxomicin [see Drug Interactions ( 7.1 )]. Table 5: Pharmacokinetic Parameters of Fidaxomicin and OP-1118 in the Presence of a Co-Administered Drug Parameter Cyclosporine 200 mg + Fidaxomicin 200 mg* (N=14) Fidaxomicin 200 mg Alone (N=14) Mean Ratio of Parameters With/Without Co- Administered Drug (90% CI † ) No Effect = 1.00 N Mean N Mean Fidaxomicin C max (ng/mL) 14 19.4 14 4.67 4.15 (3.23-5.32) AUC 0-∞ (ng-h/mL) 8 114 9 59.5 1.92 (1.39-2.64) OP-1118 C max (ng/mL) 14 100 14 10.6 9.51 (6.93-13.05) AUC 0-∞ (ng-h/mL) 12 438 10 106 4.11 (3.06-5.53) * Cyclosporine was administered 1 hour before fidaxomicin. † CI - confidence interval Fidaxomicin had no significant impact on the pharmacokinetics of the following co-administered drugs: digoxin (P-gp substrate), midazolam (CYP3A4 substrate), warfarin (CYP2C9 substrate), and omeprazole (CYP2C19 substrate). No dose adjustment is warranted when fidaxomicin is co-administered with substrates of P-gp or CYP enzymes. 12.4 Microbiology Mechanism of Action Fidaxomicin is a fermentation product obtained from the Actinomycete Dactylosporangium aurantiacum. Fidaxomicin is a macrolide antibacterial drug that inhibits RNA synthesis by binding to RNA polymerases. Fidaxomicin is bactericidal against C. difficile in vitro , and demonstrates a post-antibiotic effect vs. C. difficile of 6 to 10 hrs. Resistance Fidaxomicin demonstrates no in vitro cross-resistance with other classes of antibacterial drugs. In vitro studies indicate a low frequency of spontaneous resistance to fidaxomicin in C. difficile (ranging from <1.4 × 10 -9 to 12.8 × 10 -9 ). A specific mutation (Val-ll43-Gly) in the beta subunit of RNA polymerase is associated with reduced susceptibility to fidaxomicin. This mutation was created in the laboratory and seen during clinical trials in a C. difficile isolate obtained from an adult subject treated with fidaxomicin tablets who had recurrence of CDAD. The fidaxomicin minimum inhibitory concentration (MIC) of the C. difficil e isolate from this subject increased from a baseline of 0.06 mcg/mL to 16 mcg/mL at the time of CDAD recurrence. Interaction With Other Antimicrobials Fidaxomicin and its main metabolite OP-1118 do not exhibit any antagonistic interaction with other classes of antibacterial drugs. Synergistic interactions of fidaxomicin and OP-1118 have been observed in vitro with rifampin and rifaximin against C. difficile . Antimicrobial Activity Fidaxomicin has been shown to be active against most isolates of Clostridioides ( formerly Clostridium) difficile , both in vitro and in clinical infections [see Indications and Usage ( 1 )]. Susceptibility Testing For specific information regarding susceptibility test interpretive criteria, and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC."],"indications_and_usage":["1 INDICATIONS AND USAGE Fidaxomicin tablets are a macrolide antibacterial indicated in adult patients for the treatment of C. difficile -associated diarrhea. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of fidaxomicin tablets and other antibacterial drugs, fidaxomicin tablets should be used only to treat infections that are proven or strongly suspected to be caused by C. difficile. ( 1.2 ) 1.1 Clostridioides difficile -Associated Diarrhea Fidaxomicin tablets are indicated in adult patients for the treatment of C. difficile-associated diarrhea (CDAD). 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of fidaxomicin tablets and other antibacterial drugs, fidaxomicin tablets should be used only to treat infections that are proven or strongly suspected to be caused by C. difficile. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Pediatric use information is approved for Cubist Pharmaceuticals LLC's DIFICID ® (fidaxomicin) tablets. However, due to Cubist Pharmaceuticals LLC's marketing exclusivity rights, this drug product is not labeled with that information."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Acute hypersensitivity reactions (angioedema, dyspnea, pruritus, and rash) have been reported. If a severe hypersensitivity reaction occurs, discontinue fidaxomicin tablets. ( 5.1 ) Fidaxomicin tablets is not expected to be effective for the treatment of other types of infections due to minimal systemic absorption of fidaxomicin. Fidaxomicin tablets should only be used for the treatment of C. difficile -associated diarrhea. ( 5.2 ) Development of drug-resistant bacteria: Only use fidaxomicin tablets for infection proven or strongly suspected to be caused by C. difficile. ( 5.3 ) 5.1 Hypersensitivity Reactions Acute hypersensitivity reactions, including dyspnea, rash, pruritus, and angioedema of the mouth, throat, and face have been reported with fidaxomicin tablets. If a severe hypersensitivity reaction occurs, fidaxomicin tablets should be discontinued and appropriate therapy should be instituted. Some patients with hypersensitivity reactions to fidaxomicin tablets also reported a history of allergy to other macrolides. Physicians prescribing fidaxomicin tablets to patients with a known macrolide allergy should be aware of the possibility of hypersensitivity reactions. 5.2 Not for Use in Infections Other than C. difficile -Associated Diarrhea Fidaxomicin tablets are not expected to be effective for the treatment of other types of infections due to minimal systemic absorption of fidaxomicin [see Clinical Pharmacology ( 12.3 )]. Fidaxomicin tablets have not been studied for the treatment of infections other than CDAD. Fidaxomicin tablets should only be used for the treatment of CDAD. 5.3 Development of Drug-Resistant Bacteria Prescribing fidaxomicin tablets in the absence of proven or strongly suspected C. difficile infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria."],"clinical_studies_table":["
Clinical Response at End of TreatmentSustained Response at 25 days Post- Treatment
Fidaxomicin % (N)Vancomycin % (N)Difference (95% CI)*Fidaxomicin % (N)Vancomycin % (N)Difference (95% CI)*
Trial 1 88% (N=289) 86% (N=307) 2.6% (-2.9%, 8.0%) 70% (N=289) 57% (N=307) 12.7% (4.4%, 20.9%)
Trial 2 88% (N=253) 87% (N=256) 1.0% (-4.8%, 6.8%) 72% (N=253) 57% (N=256) 14.6% (5.8%, 23.3%)
","
Trial 1
Initial C. difficile GroupFidaxomicin n/N (%)Vancomycin n/N (%)Difference (95% CI)*
BI Isolates 44/76 (58%) 52/82 (63%) -5.5% (-20.3%, 9.5%)
Non-BI Isolates 105/126 (83%) 87/131 (66%) 16.9% (6.3%, 27.0%)
Trial 2
Initial C. difficile GroupFidaxomicin n/N (%)Vancomycin n/N (%)Difference (95% CI)*
BI Isolates 42/65 (65%) 31/60 (52%) 12.9% (-4.2%, 29.2%)
Non-BI Isolates 109/131 (83%) 77/121 (64%) 19.6% (8.7%, 30.0%)
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term carcinogenicity studies have not been conducted to evaluate the carcinogenic potential of fidaxomicin. Neither fidaxomicin nor OP-1118 was mutagenic in the Ames assay. Fidaxomicin was also negative in the rat micronucleus assay. However, fidaxomicin was clastogenic in Chinese hamster ovary cells. Fidaxomicin did not affect the fertility of male and female rats at intravenous doses of 6.3 mg/kg. The exposure (AUC 0-t ) was approximately 100 times that in humans."],"pharmacokinetics_table":["
ParameterFidaxomicinOP-1118
NValueNValue
Cmax (ng/mL) 14 5.20 ± 2.81 14 12.0 ± 6.06
Tmax (h)* 14 2.00 (1.00-5.00) 14 1.02 (1.00-5.00)
AUC0-t (ng-h/mL) 14 48.3 ± 18.4 14 103 ± 39.4
AUC 0-∞ (ng-h/mL) 9 62.9 ± 19.5 10 118 ± 43.3
t1/2 (h) 9 11.7 ± 4.80 10 11.2 ± 3.01
","
ParameterCyclosporine 200 mg + Fidaxomicin 200 mg* (N=14)Fidaxomicin 200 mg Alone (N=14)Mean Ratio of Parameters With/Without Co- Administered Drug (90% CI †) No Effect = 1.00
NMeanNMean
Fidaxomicin
Cmax (ng/mL) 14 19.4 14 4.67 4.15 (3.23-5.32)
AUC0-∞ (ng-h/mL) 8 114 9 59.5 1.92 (1.39-2.64)
OP-1118
Cmax (ng/mL) 14 100 14 10.6 9.51 (6.93-13.05)
AUC0-∞ (ng-h/mL) 12 438 10 106 4.11 (3.06-5.53)
"],"adverse_reactions_table":["
System Organ Class Adverse ReactionFidaxomicin (N=564)Vancomycin (N=583)
n (%) n (%)
Blood and Lymphatic System Disorders
Anemia 14 (2%) 12 (2%)
Neutropenia 14 (2%) 6 (1%)
Gastrointestinal Disorders
Nausea 62 (11%) 66 (11%)
Vomiting 41 (7%) 37 (6%)
Abdominal Pain 33 (6%) 23 (4%)
Gastrointestinal Hemorrhage 20 (4%) 12 (2%)
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information). Administration with Food Inform patients and caregivers that fidaxomicin tablets may be taken with or without food. Antibacterial Resistance Patients should be counseled that antibacterial drugs, including fidaxomicin tablets, should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When fidaxomicin tablets is prescribed to treat a C. difficile infection, patients should be told that, although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by fidaxomicin tablets or other antibacterial drugs in the future. Rx only APOTEX INC FIDAXOMICIN TABLETS 200 mg Manufactured by: Apotex Inc. Toronto, Ontario Canada M9L 1T9 Manufactured for: Apotex Corp. Weston, Florida 33326 Rev. 3"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Fidaxomicin tablets are administered orally with or without food. ( 2.1 ) Adults One 200 mg tablet orally twice daily for 10 days. ( 2.2 ) 2.1 Important Administration Instructions Fidaxomicin tablets are available for oral administration as 200 mg tablets. Fidaxomicin tablets are administered orally with or without food. 2.2 Adult Patients The recommended dosage for adults is one 200 mg fidaxomicin tablet orally twice daily for 10 days. Pediatric use information is approved for Cubist Pharmaceuticals LLC's DIFICID ® (fidaxomicin) tablets. However, due to Cubist Pharmaceuticals LLC's marketing exclusivity rights, this drug product is not labeled with that information."],"spl_product_data_elements":["Fidaxomicin Fidaxomicin Fidaxomicin Fidaxomicin Butylated Hydroxytoluene Hydroxypropyl Cellulose (1600000 WAMW) Magnesium Stearate MICROCRYSTALLINE CELLULOSE Polyethylene Glycol 8000 POLYVINYL ALCOHOL, UNSPECIFIED Starch, Corn Sodium Starch Glycolate Type A Potato Talc Titanium Dioxide White to off-white F200;APO structure.jpg btl-lbl-20s.jpg ctn-lbl-20s.jpg"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS 200 mg white to off-white, capsule shape, biconvex film-coated tablet. Engraved “F200” on one side, “APO” on the other side. Film-coated tablets: 200 mg ( 3 )"],"spl_patient_package_insert":["Patient Information Fidaxomicin (fye dax″ oh mye′ sin) tablets, for oral use What You Need to Know About Your Medicine Before you take fidaxomicin tablets, be sure you understand what it is for and how to take it. If you have questions about fidaxomicin tablets, ask your doctor or pharmacist. Remember that your doctor has prescribed fidaxomicin tablets only for you. Never give this medicine to anyone else. Keep this Patient Information for fidaxomicin tablets so you can read it again. What is fidaxomicin tablets? Fidaxomicin tablets is an antibiotic medicine used to treat an infection called Clostridioides difficile-associated diarrhea (CDAD) in adults. Clostridioides difficile (C-diff) is a bacterium that can cause an infection that can damage your colon and cause stomach pain and severe diarrhea. Fidaxomicin tablets are not to be used to treat other types of infections in the body. Sometimes infections are caused by viruses rather than bacteria. Antibiotic medicines, including fidaxomicin tablets, do not kill viruses. It is not known if fidaxomicin tablets are safe and effective in children under 6 months old. Who should not take fidaxomicin tablets? Do not take fidaxomicin tablets if you are allergic to fidaxomicin, or any other ingredient in fidaxomicin tablets. See the end of this Patient Information for a complete list of ingredients in fidaxomicin tablets. What should I tell my doctor before taking fidaxomicin tablets? Pregnancy If you are pregnant or plan to become pregnant, tell your doctor before you take fidaxomicin tablets. It is not known if fidaxomicin tablets will harm your baby while you are pregnant. If you are pregnant, you and your doctor should decide together if you will take fidaxomicin tablets. Breastfeeding If you are breastfeeding or plan to breastfeed, tell your doctor before you take fidaxomicin tablets. It is not known if fidaxomicin passes into breast milk. If you are breastfeeding, you and your doctor should decide together if you will take fidaxomicin tablets. Other Medicines Tell your doctor about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal and dietary supplements. Know the medicines you take. Keep a list of your medicines to show your doctor and pharmacist when you get a new medicine. Allergic Reactions See “ Who should not take fidaxomicin tablets? ” If you are allergic to other kinds of antibiotics called macrolides (for example: azithromycin (Zithromax) or clarithromycin (Biaxin)) or any other ingredient in fidaxomicin tablets, tell your doctor. See the end of this Patient Information for a complete list of ingredients in fidaxomicin tablets. How do I take fidaxomicin tablets? Take fidaxomicin tablets exactly as prescribed by your doctor. Take fidaxomicin tablets twice a day (approximately every 12 hours). For example, if you take your first dose at 8:00 a.m. you should take your second dose at 8:00 p.m. You can take fidaxomicin tablets with or without food. Do not skip any doses or stop taking fidaxomicin tablets until you finish your prescribed treatment, even if you begin to feel better, unless you have a serious allergic reaction (see “ What are the possible side effects of fidaxomicin tablets? ”). This will lower the chance that the bacteria will become resistant to fidaxomicin tablets. If this happens, fidaxomicin tablets and other antibiotic medicines may not work in the future. What are the possible side effects of fidaxomicin tablets? Fidaxomicin tablets can cause serious side effects, including : Allergic reaction . If you get a severe allergic reaction while taking fidaxomicin tablets, including problems breathing or shortness of breath, rash, itching or hives, or swelling of the mouth, throat, or face, stop taking fidaxomicin tablets and get emergency medical help right away. Common side effects of fidaxomicin tablets include: The most common side effects of fidaxomicin tablets in adults include: nausea bleeding in the stomach or intestines vomiting low red blood cell count (anemia) stomach pain low white blood cell count (neutropenia) Other less common side effects of fidaxomicin tablets may include: swelling of any body part (such as your face, lips, tongue or around your eyes) passing gas itching intestinal blockage hives serious bowel inflammation (toxic megacolon) bloating low platelet count (important for clotting and to control bleeding) stomach tenderness high levels of acid in your blood (metabolic acidosis) heartburn problems swallowing high blood sugar (hyperglycemia) abnormal liver tests low levels of blood bicarbonate If you have any side effect that bothers you or does not go away, tell your doctor. There may be other side effects to fidaxomicin tablets that are not listed. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store fidaxomicin tablets? Store fidaxomicin tablets at room temperature between 68°F to 77°F (20°C to 25°C). Keep fidaxomicin tablets in its original bottle until you are ready to take it. Keep fidaxomicin tablets and all medicines out of the reach of children. General information about the safe and effective use of fidaxomicin tablets. Medicines are sometimes prescribed for purposes other than those listed in the Patient Information. Do not take fidaxomicin tablets for a condition for which it was not prescribed. Do not give fidaxomicin tablets to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or doctor for information about fidaxomicin tablets that is written for health professionals. What if I have questions? Call your doctor. Call Apotex Corp, the company that makes fidaxomicin tablets at 1-800-706-5575. Go to the website – www.apotex.com. You can also find the full prescribing information written for doctors at www.apotex.com What are the ingredients in fidaxomicin tablets? Active ingredient : fidaxomicin. Inactive ingredients : butylated hydroxytoluene, hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, pregelatinized starch, sodium starch glycolate, talc, and titanium dioxide. Pediatric use information is approved for Cubist Pharmaceuticals LLC's DIFICID ® (fidaxomicin) tablets. However, due to Cubist Pharmaceuticals LLC's marketing exclusivity rights, this drug product is not labeled with that information. All registered trademarks in this document are the property of their respective owners. This Patient Information has been approved by the U.S. Food and Drug Administration. Rx only APOTEX INC FIDAXOMICIN TABLETS 200 mg Manufactured by: Apotex Inc. Toronto, Ontario Canada M9L 1T9 Manufactured for: Apotex Corp. Weston, Florida 33326 Revised: May 2025 Rev. 3"],"clinical_pharmacology_table":["
ParameterFidaxomicinOP-1118
NValueNValue
Cmax (ng/mL) 14 5.20 ± 2.81 14 12.0 ± 6.06
Tmax (h)* 14 2.00 (1.00-5.00) 14 1.02 (1.00-5.00)
AUC0-t (ng-h/mL) 14 48.3 ± 18.4 14 103 ± 39.4
AUC 0-∞ (ng-h/mL) 9 62.9 ± 19.5 10 118 ± 43.3
t1/2 (h) 9 11.7 ± 4.80 10 11.2 ± 3.01
","
ParameterCyclosporine 200 mg + Fidaxomicin 200 mg* (N=14)Fidaxomicin 200 mg Alone (N=14)Mean Ratio of Parameters With/Without Co- Administered Drug (90% CI †) No Effect = 1.00
NMeanNMean
Fidaxomicin
Cmax (ng/mL) 14 19.4 14 4.67 4.15 (3.23-5.32)
AUC0-∞ (ng-h/mL) 8 114 9 59.5 1.92 (1.39-2.64)
OP-1118
Cmax (ng/mL) 14 100 14 10.6 9.51 (6.93-13.05)
AUC0-∞ (ng-h/mL) 12 438 10 106 4.11 (3.06-5.53)
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Pediatrics: The safety and effectiveness of fidaxomicin tablets have not been established in pediatric patients younger than 6 months of age. ( 8.4 ) Pediatric use information is approved for Cubist Pharmaceuticals LLC's DIFICID ® (fidaxomicin) tablets. However, due to Cubist Pharmaceuticals LLC's marketing exclusivity rights, this drug product is not labeled with that information. 8.1 Pregnancy Risk Summary The limited available data on use of fidaxomicin tablets in pregnant women are insufficient to inform any drug-associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes. Embryo-fetal reproduction studies in rats and rabbits dosed intravenously during organogenesis revealed no evidence of harm to the fetus at fidaxomicin and OP-1118 (its main metabolite) exposures 65-fold or higher than the clinical exposure at the fidaxomicin tablets recommended dose [see Data]. The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data In pregnant rats, fidaxomicin was administered intravenously at doses of 4, 8, and 15 mg/kg/day from gestation day 6 through 17 (during the period of organogenesis). No embryo/fetal effects were noted in this study at exposures (AUC) 193-fold higher for fidaxomicin, and 65-fold higher for OP-1118 than the clinical exposure at the fidaxomicin tablets recommended dose. In pregnant rabbits, fidaxomicin was administered intravenously at doses of 2, 4, and 7.5 mg/kg/day from gestation day 6 through 18 (during the period of organogenesis). No embryo/fetal effects were noted in this study at exposures 66-fold higher for fidaxomicin, and 245-fold higher for OP-1118 than the clinical exposure at the fidaxomicin tablets recommended dose. 8.2 Lactation Risk Summary There is no information on the presence of fidaxomicin or its main metabolite, OP-1118, in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for fidaxomicin tablets and any potential adverse effects on the breastfed infant from fidaxomicin tablets or from the underlying maternal condition. 8.4 Pediatric Use The safety and effectiveness of fidaxomicin tablets have not been established in pediatric patients younger than 6 months of age. Pediatric use information is approved for Cubist Pharmaceuticals LLC's DIFICID ® (fidaxomicin) tablets. However, due to Cubist Pharmaceuticals LLC's marketing exclusivity rights, this drug product is not labeled with that information. 8.5 Geriatric Use Of the total number of patients in controlled trials of fidaxomicin tablets, 50% were 65 years of age and over, while 31% were 75 and over. No overall differences in safety or effectiveness of fidaxomicin tablets compared to vancomycin were observed between these subjects and younger subjects. In controlled trials, elderly patients (≥65 years of age) had higher plasma concentrations of fidaxomicin and its main metabolite, OP-1118, versus non-elderly patients (<65 years of age) [see Clinical Pharmacology ( 12.3 )]. However, greater exposures in elderly patients were not considered to be clinically significant. No dose adjustment is recommended for elderly patients."],"information_for_patients_table":["
Manufactured by: Apotex Inc. Toronto, Ontario Canada M9L 1T9 Manufactured for: Apotex Corp. Weston, Florida 33326
"],"spl_patient_package_insert_table":["
If you have any side effect that bothers you or does not go away, tell your doctor.
","
Manufactured by: Apotex Inc. Toronto, Ontario Canada M9L 1T9 Manufactured for: Apotex Corp. Weston, Florida 33326
"],"package_label_principal_display_panel":["PACKAGE LABEL PRINCIPAL DISPLAY PANEL - Bottle Label NDC 60505-4833-2 Fidaxomicin Tablets 200 mg Bottle of 20 Tablets Rx only","PACKAGE LABEL PRINCIPAL DISPLAY PANEL - Carton Label NDC 60505-4833-2 Fidaxomicin Tablets 200 mg Bottle of 20 Tablets Rx only"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term carcinogenicity studies have not been conducted to evaluate the carcinogenic potential of fidaxomicin. Neither fidaxomicin nor OP-1118 was mutagenic in the Ames assay. Fidaxomicin was also negative in the rat micronucleus assay. However, fidaxomicin was clastogenic in Chinese hamster ovary cells. Fidaxomicin did not affect the fertility of male and female rats at intravenous doses of 6.3 mg/kg. The exposure (AUC 0-t ) was approximately 100 times that in humans."]},"tags":[{"label":"Macrolide Antibacterial","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"A07AA12","category":"atc"},{"label":"Oral","category":"route"},{"label":"Granule","category":"form"},{"label":"Tablet","category":"form"},{"label":"Generic Available","category":"availability"},{"label":"LOE Approaching","category":"status"},{"label":"Clostridium difficile infection","category":"indication"},{"label":"Pseudomembranous enterocolitis","category":"indication"},{"label":"Cubist Pharms Llc","category":"company"},{"label":"Approved 2010s","category":"decade"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":327.218,"date":"","count":96,"signal":"Clostridium difficile infection","source":"DrugCentral FAERS","actionTaken":"Reported 96 times (LLR=327)"},{"llr":191.636,"date":"","count":65,"signal":"Disease recurrence","source":"DrugCentral FAERS","actionTaken":"Reported 65 times (LLR=192)"},{"llr":116.956,"date":"","count":137,"signal":"Diarrhoea","source":"DrugCentral FAERS","actionTaken":"Reported 137 times (LLR=117)"},{"llr":106.252,"date":"","count":155,"signal":"Drug ineffective","source":"DrugCentral FAERS","actionTaken":"Reported 155 times (LLR=106)"},{"llr":104.797,"date":"","count":38,"signal":"Clostridium difficile colitis","source":"DrugCentral FAERS","actionTaken":"Reported 38 times (LLR=105)"},{"llr":71.879,"date":"","count":19,"signal":"Clostridium test positive","source":"DrugCentral FAERS","actionTaken":"Reported 19 times (LLR=72)"},{"llr":69.91,"date":"","count":55,"signal":"Treatment failure","source":"DrugCentral FAERS","actionTaken":"Reported 55 times (LLR=70)"},{"llr":68.945,"date":"","count":18,"signal":"Pseudomembranous colitis","source":"DrugCentral FAERS","actionTaken":"Reported 18 times (LLR=69)"},{"llr":58.068,"date":"","count":8,"signal":"Avian influenza","source":"DrugCentral FAERS","actionTaken":"Reported 8 times (LLR=58)"},{"llr":55.165,"date":"","count":30,"signal":"No adverse event","source":"DrugCentral FAERS","actionTaken":"Reported 30 times (LLR=55)"},{"llr":42.957,"date":"","count":8,"signal":"Renal graft infection","source":"DrugCentral FAERS","actionTaken":"Reported 8 times (LLR=43)"},{"llr":41.494,"date":"","count":31,"signal":"Septic shock","source":"DrugCentral FAERS","actionTaken":"Reported 31 times (LLR=41)"}],"commonSideEffects":[{"effect":"Abdominal pain","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Vomiting","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Diarrhea","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Constipation","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Pyrexia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Gastrointestinal hemorrhage","drugRate":"4%","severity":"mild","_validated":true},{"effect":"Anemia","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Neutropenia","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Nausea","drugRate":"11%","severity":"common","_validated":true},{"effect":"Abdominal distension","drugRate":"reported","severity":"unknown"},{"effect":"Abdominal tenderness","drugRate":"reported","severity":"unknown"},{"effect":"Dyspepsia","drugRate":"reported","severity":"unknown"},{"effect":"Dysphagia","drugRate":"reported","severity":"unknown"},{"effect":"Flatulence","drugRate":"reported","severity":"unknown"},{"effect":"Intestinal obstruction","drugRate":"reported","severity":"unknown"},{"effect":"Megacolon","drugRate":"reported","severity":"unknown"},{"effect":"Increased blood alkaline phosphatase","drugRate":"reported","severity":"unknown"},{"effect":"Decreased blood bicarbonate","drugRate":"reported","severity":"unknown"},{"effect":"Increased hepatic enzymes","drugRate":"reported","severity":"unknown"},{"effect":"Decreased platelet count","drugRate":"reported","severity":"unknown"},{"effect":"Hyperglycemia","drugRate":"reported","severity":"unknown"},{"effect":"Metabolic acidosis","drugRate":"reported","severity":"unknown"},{"effect":"Drug eruption","drugRate":"reported","severity":"unknown"},{"effect":"Pruritus","drugRate":"reported","severity":"unknown"},{"effect":"Rash","drugRate":"reported","severity":"unknown"},{"effect":"Urticaria","drugRate":"reported","severity":"unknown"},{"effect":"Hypersensitivity reactions","drugRate":"reported","severity":"unknown"}],"specialPopulations":{"Pregnancy":"The limited available data on use of DIFICID in pregnant women are insufficient to inform any drug-associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes. Embryo-fetal reproduction studies in rats and rabbits dosed intravenously during organogenesis revealed no evidence of harm to the fetus at fidaxomicin and OP-1118 (its main metabolite) exposures 65-fold or higher than the clinical exposure at the DIFICID recommended dose.","Geriatric use":"Of the total number of patients in controlled trials of DIFICID, 50% were 65 years of age and over, while 31% were 75 and over. No overall differences in safety or effectiveness of DIFICID compared to vancomycin were observed between these subjects and younger subjects.","Paediatric use":"The safety and effectiveness of DIFICID for the treatment of CDAD have been established in pediatric patients 3 months to less than 18 years of age. Use of DIFICID in these age groups is supported by evidence from adequate and well-controlled trials of DIFICID in adults with CDAD and pharmacokinetic, safety and efficacy data from pediatric trials."}},"trials":[],"aliases":[],"company":"Cubist Pharms Llc","patents":[{"applNo":"N213138","source":"FDA Orange Book","status":"Active","expires":"Mar 4, 2027","useCode":"U-2741","territory":"US","drugProduct":false,"patentNumber":"7906489","drugSubstance":false},{"applNo":"N213138","source":"FDA Orange Book","status":"Active","expires":"Jul 31, 2027","useCode":"U-2741","territory":"US","drugProduct":false,"patentNumber":"8859510","drugSubstance":false},{"applNo":"N213138","source":"FDA Orange Book","status":"Active","expires":"Jul 31, 2027","useCode":"","territory":"US","drugProduct":true,"patentNumber":"7378508","drugSubstance":true},{"applNo":"N213138","source":"FDA Orange Book","status":"Active","expires":"Jul 31, 2027","useCode":"","territory":"US","drugProduct":true,"patentNumber":"7863249","drugSubstance":false},{"applNo":"N213138","source":"FDA Orange Book","status":"Active","expires":"May 28, 2034","useCode":"","territory":"US","drugProduct":true,"patentNumber":"9808530","drugSubstance":false},{"applNo":"N213138","source":"FDA Orange Book","status":"Active","expires":"Nov 28, 2034","useCode":"","territory":"US","drugProduct":false,"patentNumber":"9808530*PED","drugSubstance":false},{"applNo":"N213138","source":"FDA Orange Book","status":"Active","expires":"Jan 31, 2028","useCode":"","territory":"US","drugProduct":false,"patentNumber":"7378508*PED","drugSubstance":false},{"applNo":"N213138","source":"FDA Orange Book","status":"Active","expires":"Sep 4, 2027","useCode":"","territory":"US","drugProduct":false,"patentNumber":"7906489*PED","drugSubstance":false},{"applNo":"N213138","source":"FDA Orange Book","status":"Active","expires":"Jan 31, 2028","useCode":"","territory":"US","drugProduct":false,"patentNumber":"7863249*PED","drugSubstance":false},{"applNo":"N213138","source":"FDA Orange Book","status":"Active","expires":"Jan 31, 2028","useCode":"","territory":"US","drugProduct":false,"patentNumber":"8859510*PED","drugSubstance":false}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=FIDAXOMICIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:41:30.515132+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T03:41:28.795933+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:41:36.109129+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FIDAXOMICIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:41:36.446173+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:41:27.002195+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:41:27.002232+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:41:27.002238+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4077022/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:41:37.159695+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA219559","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:41:27.002243+00:00"}},"allNames":"dificid","offLabel":[],"synonyms":["lipiarmicin","lipiarmycin","tiacumicin B","dificid","fidaxomicin","dificlir"],"timeline":[{"date":"2011-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from CUBIST PHARMS to Cubist Pharms Llc"},{"date":"2011-05-27","type":"positive","source":"DrugCentral","milestone":"FDA approval (Cubist Pharms)"},{"date":"2018-07-02","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Astellas Pharma Inc)"},{"date":"2026-02-02","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 3 manufacturers approved"},{"date":"2027-01-24","type":"negative","source":"FDA Orange Book","milestone":"ODE-367 exclusivity expires"},{"date":"2027-07-31","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 7378508 expires"}],"aiSummary":"Dificid (fidaxomicin) is a macrolide antibacterial drug originally developed by Cubist Pharms and currently owned by Cubist Pharms LLC. It is a small molecule that was FDA-approved in 2011 for the treatment of Clostridium difficile infection and pseudomembranous enterocolitis. Dificid is commercially available, with multiple generic manufacturers. Key safety considerations include the potential for gastrointestinal side effects. The commercial status of Dificid is not off-patent.","approvals":[{"date":"2011-05-27","orphan":false,"company":"CUBIST PHARMS","regulator":"FDA"},{"date":"2018-07-02","orphan":false,"company":"Astellas Pharma Inc","regulator":"PMDA"}],"brandName":"Dificid","ecosystem":[{"indication":"Clostridium difficile infection","otherDrugs":[{"name":"bezlotoxumab","slug":"bezlotoxumab","company":"Merck Sharp Dohme"}],"globalPrevalence":null},{"indication":"Pseudomembranous enterocolitis","otherDrugs":[{"name":"vancomycin","slug":"vancomycin","company":""}],"globalPrevalence":3600000}],"mechanism":{"novelty":"Follow-on","modality":"Small Molecule","drugClass":"Macrolide Antibacterial [EPC]","explanation":"Fidaxomicin is an antibacterial drug [see Microbiology (12.4)].","oneSentence":"Dificid works by inhibiting protein synthesis in bacteria, preventing them from reproducing and causing infection.","technicalDetail":"Fidaxomicin is a 20-membered macrolide antibiotic that binds to the 50S ribosomal subunit of bacteria, inhibiting peptide bond formation and thus preventing protein synthesis."},"commercial":{"launchDate":"2011","revenueYear":2025,"_launchSource":"DrugCentral (FDA 2011-05-27, CUBIST PHARMS)","annualRevenue":410,"revenueSource":"Teva 2026-02-03 (verified from SEC filing)","revenueCurrency":"USD","revenueConfidence":"high"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4180","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=FIDAXOMICIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FIDAXOMICIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T11:31:09.703863","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:41:40.866556+00:00","fieldsConflicting":5,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"neomycin","drugSlug":"neomycin","fdaApproval":"1957-03-26","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"nystatin","drugSlug":"nystatin","fdaApproval":"1964-07-08","genericCount":48,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"natamycin","drugSlug":"natamycin","fdaApproval":"1978-10-30","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"streptomycin","drugSlug":"streptomycin","fdaApproval":"1946-02-18","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"Polymyxin B","drugSlug":"polymyxin-b","fdaApproval":"1957-03-26","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"paromomycin","drugSlug":"paromomycin","fdaApproval":"1969-03-24","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"amphotericin B","drugSlug":"amphotericin-b","fdaApproval":"1964-11-12","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"kanamycin","drugSlug":"kanamycin","fdaApproval":"1973-02-13","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"vancomycin","drugSlug":"vancomycin","fdaApproval":"1964-11-06","patentExpiry":"Nov 6, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"colistin","drugSlug":"colistin","fdaApproval":"1962-05-17","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"rifaximin","drugSlug":"rifaximin","fdaApproval":"2004-05-25","patentExpiry":"Sep 2, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"rifamycin","drugSlug":"rifamycin","fdaApproval":"2018-11-16","patentStatus":"Unknown","relationship":"same-class"}],"exclusivity":[{"code":"ODE-367","date":"Jan 24, 2027"}],"genericName":"fidaxomicin","indications":{"approved":[{"name":"Clostridium difficile infection","source":"DrugCentral","snomedId":186431008,"regulator":"FDA"},{"name":"Pseudomembranous enterocolitis","source":"DrugCentral","snomedId":397683000,"regulator":"FDA","usPrevalence":null,"globalPrevalence":3600000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (European Medicines Agency 2015[INST])"}],"offLabel":[],"pipeline":[]},"currentOwner":"Cubist Pharms Llc","drugCategory":"loe-approaching","labelChanges":[],"relatedDrugs":[{"drugId":"neomycin","brandName":"neomycin","genericName":"neomycin","approvalYear":"1957","relationship":"same-class"},{"drugId":"nystatin","brandName":"nystatin","genericName":"nystatin","approvalYear":"1964","relationship":"same-class"},{"drugId":"natamycin","brandName":"natamycin","genericName":"natamycin","approvalYear":"1978","relationship":"same-class"},{"drugId":"streptomycin","brandName":"streptomycin","genericName":"streptomycin","approvalYear":"1946","relationship":"same-class"},{"drugId":"polymyxin-b","brandName":"Polymyxin B","genericName":"Polymyxin B","approvalYear":"1957","relationship":"same-class"},{"drugId":"paromomycin","brandName":"paromomycin","genericName":"paromomycin","approvalYear":"1969","relationship":"same-class"},{"drugId":"amphotericin-b","brandName":"amphotericin B","genericName":"amphotericin B","approvalYear":"1964","relationship":"same-class"},{"drugId":"kanamycin","brandName":"kanamycin","genericName":"kanamycin","approvalYear":"1973","relationship":"same-class"},{"drugId":"vancomycin","brandName":"vancomycin","genericName":"vancomycin","approvalYear":"1964","relationship":"same-class"},{"drugId":"colistin","brandName":"colistin","genericName":"colistin","approvalYear":"1962","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07328971","phase":"PHASE3","title":"Vancomycin Taper to Prevent Recurrent Clostridioides Difficile","status":"NOT_YET_RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2026-06-01","conditions":["Clostridia Difficile Colitis"],"enrollment":500,"completionDate":"2030-11-01"},{"nctId":"NCT02667418","phase":"PHASE4","title":"Optimal Treatment for Recurrent Clostridium Difficile","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2016-02-19","conditions":["Clostridium","Difficile","Fidaxomicin","Vancomycin"],"enrollment":308,"completionDate":"2024-08-31"},{"nctId":"NCT06794944","phase":"PHASE4","title":"Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-09","conditions":["Inflammatory Bowel Disease (IBD)","Clostridioides Difficile Infection"],"enrollment":60,"completionDate":"2031-09"},{"nctId":"NCT06884748","phase":"EARLY_PHASE1","title":"Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2025-12-01","conditions":["Clostridioides Difficile Infection"],"enrollment":30,"completionDate":"2028-05-01"},{"nctId":"NCT05266807","phase":"PHASE3","title":"Fecal Microbiota Transplantation in Clostridioides Difficile Infection First Episode and First Recurrence","status":"RECRUITING","sponsor":"Benoit Guery","startDate":"2023-03-15","conditions":["Clostridioides Difficile Infection"],"enrollment":220,"completionDate":"2028-01-31"},{"nctId":"NCT07120490","phase":"NA","title":"STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile Infection","status":"NOT_YET_RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2025-10","conditions":["Clostridioides Difficile Infection","Clostridioides Difficile Infection Recurrence","Fecal Microbiota Transplantation (FMT)","Comparative Effectiveness of CDI Treatments","Fidaxomicin","Vancomycin"],"enrollment":424,"completionDate":"2027-04-30"},{"nctId":"NCT05201079","phase":"PHASE3","title":"Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin","status":"COMPLETED","sponsor":"Mikrobiomik Healthcare Company S.L.","startDate":"2021-10-29","conditions":["Recurrent Clostridium Difficile Infection","Primary Clostridium Difficile Infection"],"enrollment":93,"completionDate":"2023-11-15"},{"nctId":"NCT02218372","phase":"PHASE3","title":"A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","isPivotal":true,"startDate":"2015-01-09","conditions":["Clostridium Difficile-associated Diarrhea (CDAD)"],"enrollment":148,"completionDate":"2018-03-07"},{"nctId":"NCT02437591","phase":"PHASE4","title":"Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2015-08-13","conditions":["Inflammatory Bowel Disease (IBD)","Clostridium Difficile Infection (CDI)"],"enrollment":25,"completionDate":"2016-10-24"},{"nctId":"NCT02179658","phase":"PHASE3","title":"A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-06-23","conditions":["Clostridium Difficile"],"enrollment":210,"completionDate":"2016-09-08"},{"nctId":"NCT02254967","phase":"PHASE4","title":"A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2014-11-06","conditions":["Clostridium Difficile"],"enrollment":364,"completionDate":"2016-05-05"},{"nctId":"NCT04070352","phase":"","title":"Evaluation of Fidaxomicin in the Treatment of Clostridium Difficile Infection (CDI)","status":"WITHDRAWN","sponsor":"University of Pittsburgh","startDate":"2019-08-01","conditions":["Clostridium Difficile Infection (CDI)"],"enrollment":0,"completionDate":"2023-05-01"},{"nctId":"NCT05447533","phase":"NA","title":"Clostridioides Difficile and Frailty","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2022-09-16","conditions":["Frail Elderly","Clostridioides Difficile","Geriatric Assessment","Faecal Microbiota Transplantation","Aged"],"enrollment":217,"completionDate":"2023-08-16"},{"nctId":"NCT03182907","phase":"PHASE3","title":"Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-03-27","conditions":["Clostridium Difficile Infection"],"enrollment":148,"completionDate":"2022-05-12"},{"nctId":"NCT05077085","phase":"PHASE4","title":"Bezlotoxumab Versus FMT for Multiple Recurrent CDI","status":"WITHDRAWN","sponsor":"Leiden University Medical Center","startDate":"2022-01","conditions":["Clostridium Infections","Clostridioides Difficile","Enterocolitis, Pseudomembranous"],"enrollment":0,"completionDate":"2024-12"},{"nctId":"NCT02395848","phase":"PHASE3","title":"Efficacy of 30-day Duration of Fidaxomicin for Recurrent C. Difficile Infection","status":"TERMINATED","sponsor":"McMaster University","startDate":"2015-07","conditions":["Clostridium Difficile Infection"],"enrollment":31,"completionDate":"2021-08-30"},{"nctId":"NCT04317963","phase":"","title":"Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2020-02-12","conditions":["Clostridium Difficile Infection","Clostridium Difficile Infection Recurrence"],"enrollment":180,"completionDate":"2023-02-22"},{"nctId":"NCT03760484","phase":"PHASE2","title":"Fecal Microbiota Transplant (FMT) Plus Fidaxomicin for Severe or Fulminant Clostridium Difficile Infection","status":"TERMINATED","sponsor":"University of Alberta","startDate":"2019-01-21","conditions":["Clostridium Difficile"],"enrollment":4,"completionDate":"2020-03-10"},{"nctId":"NCT02692651","phase":"PHASE4","title":"A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2017-05-01","conditions":["Clostridium Difficile Infection (CDI)"],"enrollment":144,"completionDate":"2021-06-23"},{"nctId":"NCT02461901","phase":"","title":"Does Fidaxomicin Therapy Reduce Spread of Clostridium Difficile?","status":"COMPLETED","sponsor":"Professor Mark Wilcox","startDate":"2015-01","conditions":["Clostridium Difficile Infection"],"enrollment":203,"completionDate":"2017-12"},{"nctId":"NCT01775397","phase":"PHASE4","title":"A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System","status":"TERMINATED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2012-11-29","conditions":["Clostridium Difficile"],"enrollment":12,"completionDate":"2013-04-15"},{"nctId":"NCT02743234","phase":"PHASE3","title":"Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2016-04","conditions":["Clostridium Difficile Infection"],"enrollment":64,"completionDate":"2019-08-31"},{"nctId":"NCT02057198","phase":"PHASE4","title":"Impact of Oral Antibiotic Treatment on C. Difficile","status":"COMPLETED","sponsor":"Duke University","startDate":"2014-06-10","conditions":["C. Difficile","Diarrhea","Enterocolitis"],"enrollment":33,"completionDate":"2017-06-27"},{"nctId":"NCT01591863","phase":"PHASE2","title":"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)","status":"COMPLETED","sponsor":"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2012-06-15","conditions":["Clostridium Difficile-associated Diarrhea"],"enrollment":38,"completionDate":"2014-03-07"},{"nctId":"NCT01691248","phase":"PHASE3","title":"Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001)","status":"COMPLETED","sponsor":"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2012-10-10","conditions":["Clostridium Difficile-Associated Diarrhea (CDAD)"],"enrollment":611,"completionDate":"2015-04-16"},{"nctId":"NCT01241552","phase":"PHASE3","title":"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-10","conditions":["Clostridium Difficile Infection"],"enrollment":1452,"completionDate":"2014-12-09"},{"nctId":"NCT01513239","phase":"PHASE3","title":"A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02-01","conditions":["Clostridium Difficile Infection"],"enrollment":1203,"completionDate":"2015-05-22"},{"nctId":"NCT02464306","phase":"PHASE4","title":"Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile Infection","status":"WITHDRAWN","sponsor":"University of Colorado, Denver","startDate":"2018-06","conditions":["Clostridium Difficile Infection","Solid Organ Transplant"],"enrollment":0,"completionDate":"2019-06"},{"nctId":"NCT02784002","phase":"PHASE2","title":"A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)","status":"COMPLETED","sponsor":"Summit Therapeutics","startDate":"2014-12","conditions":["Clostridium Difficile Infection"],"enrollment":27,"completionDate":"2016-08"},{"nctId":"NCT02214771","phase":"","title":"Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients","status":"COMPLETED","sponsor":"Astellas Pharma S.A.S.","startDate":"2014-09-03","conditions":["Clostridium Difficile Infection"],"enrollment":296,"completionDate":"2017-08-17"},{"nctId":"NCT01818141","phase":"PHASE4","title":"Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin","status":"COMPLETED","sponsor":"Hartford Hospital","startDate":"2012-10-17","conditions":["Clostridium Difficile Infection"],"enrollment":34,"completionDate":"2014-12-15"},{"nctId":"NCT00468728","phase":"PHASE3","title":"PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)","status":"COMPLETED","sponsor":"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2006-10-04","conditions":["Clostridium Infections","Diarrhea"],"enrollment":535,"completionDate":"2009-12-11"},{"nctId":"NCT00314951","phase":"PHASE3","title":"Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)","status":"COMPLETED","sponsor":"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2006-05-02","conditions":["Clostridium Infections","Diarrhea"],"enrollment":629,"completionDate":"2008-08-21"},{"nctId":"NCT03053505","phase":"NA","title":"A Novel Faecal Microbiota Transplantation System for Treatment of Primary and Recurrent Clostridium Difficile Infection","status":"UNKNOWN","sponsor":"Sejtterapia Kozpont Kft.","startDate":"2017-01","conditions":["Clostridium Difficile Infection"],"enrollment":150,"completionDate":"2018-10"},{"nctId":"NCT02355938","phase":"PHASE4","title":"Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord Injury","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2014-02","conditions":["Clostridium Difficile","Spinal Cord Injury"],"enrollment":12,"completionDate":"2016-10"},{"nctId":"NCT01533844","phase":"","title":"To Determine the Feasibility of a Fidaxomicin Study in Neonates and to Assess C. Difficile (Clostridium Difficile) Involvement in the Pathogenesis","status":"TERMINATED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2012-03","conditions":["Clostridium Difficile"],"enrollment":1,"completionDate":"2014-09"},{"nctId":"NCT01552668","phase":"PHASE4","title":"Fidaxomicin to Prevent Clostridium Difficile Colonization","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2012-09","conditions":["Clostridium Difficile Infection"],"enrollment":0,"completionDate":"2013-12"},{"nctId":"NCT01813448","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2013-02","conditions":["Pharmacokinetics of Fidaxomicin","Healthy Subjects"],"enrollment":36,"completionDate":"2013-04"},{"nctId":"NCT02083627","phase":"PHASE1","title":"A Study to Assess the Effects of Multiple Doses of Fidaxomicin on a Single Dose of Rosuvastatin in Healthy Male Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2013-02","conditions":["Drug-Drug Interaction (DDI)","Intestinal Absorption","Healthy Subjects","Pharmacokinetics of Rosuvastatin","Pharmacokinetics of Fidaxomicin"],"enrollment":25,"completionDate":"2013-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"pivotalTrials":["NCT02218372"],"administration":{"route":"Oral","formulation":"Granule, Tablet","formulations":[{"form":"GRANULE, FOR SUSPENSION","route":"ORAL","productName":"DIFICID"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Dificid"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000182832","MMSL":"181510","NDDF":"013814","UNII":"Z5N076G8YQ","VUID":"4030846","CHEBI":"CHEBI:68590","VANDF":"4030846","INN_ID":"9038","RXNORM":"1111103","UMLSCUI":"C0065023","chemblId":"CHEMBL4077022","ChEMBL_ID":"CHEMBL1255800","KEGG_DRUG":"D09394","DRUGBANK_ID":"DB08874","PDB_CHEM_ID":" FI8","PUBCHEM_CID":"10034073","SNOMEDCT_US":"703664004","IUPHAR_LIGAND_ID":"10909","MESH_DESCRIPTOR_UI":"D000077732"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2011-","companyName":"Cubist Pharms","relationship":"Original Developer"},{"period":"present","companyName":"Cubist Pharms Llc","relationship":"Current Owner"},{"period":"2018","companyName":"Astellas Pharma Inc","relationship":"PMDA Licensee"}],"publicationCount":840,"therapeuticAreas":["Immunology"],"_revenueScrapedAt":"2026-03-31 14:09:27.196735+00","atcClassification":{"source":"DrugCentral","atcCode":"A07AA12","allCodes":["A07AA12"]},"biosimilarFilings":[],"originalDeveloper":"Cubist Pharms","recentPublications":[{"date":"2026 Apr","pmid":"41846263","title":"Ionomycin Exhibits Potent and Selective Bactericidal Activity Against Clostridioides difficile Through Calcium-Dependent Membrane Disruption.","journal":"MicrobiologyOpen"},{"date":"2026 Feb","pmid":"41841080","title":"An Unlikely Culprit: Novel Case of Vancomycin Oral Solution-Induced Agranulocytosis.","journal":"Cureus"},{"date":"2026","pmid":"41813198","title":"Diagnosis and Treatment of Clostridioides difficile Infection.","journal":"Journal of Nippon Medical School = Nippon Ika Daigaku zasshi"},{"date":"2026 Mar","pmid":"41808698","title":"Refractory Clostridioides difficile Colitis in a Patient With Hidradenitis Suppurativa: Consequences of Long-Term Clindamycin and Multi-agent Anti-TNF Therapy.","journal":"Cureus"},{"date":"2026 Mar 5","pmid":"41770247","title":"Ribotype distribution of Clostridioides difficile isolated from patients with diarrhea in Ahvaz, Iran.","journal":"Acta microbiologica et immunologica Hungarica"}],"companionDiagnostics":[],"genericManufacturers":3,"_genericFilersChecked":true,"genericManufacturerList":["Actavis Labs Fl","Apotex","Torrent"],"status":"approved","companyName":"Cubist Pharms Llc","companyId":"cubist-pharms-llc","modality":"Small molecule","firstApprovalDate":"2011","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2011-05-27T00:00:00.000Z","mah":"CUBIST PHARMS","brand_name_local":null,"application_number":""},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2018-07-02T00:00:00.000Z","mah":"Astellas Pharma Inc","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":"EMEA/H/C/002087"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dificlir","application_number":null},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":2},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:41:40.866556+00:00","fieldsConflicting":5,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}